Latus Bio, Inc. (Latus), a biotechnology company pioneering advances in AAV gene therapy, is pleased to announce data ...

LETI-101 has demonstrated therapeutically relevant reductions of mutant huntingtin (HTT) protein, exceeding 80%, while preserving essential ...

PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transfo ...

PepGen Inc. , a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological ...

A new discovery offers hope for Huntington’s disease. This discovery provides hope that a DNA repair process may help slow or ...

The expansion of CAG trinucleotide repeats located in the coding sequence (CDS) of various human genes is associated with the development of neurodegenerative disorders (NDs), including Huntington’s ...

This study presents valuable findings by using Fmr1 knockout mice as a model to investigate the role of Fmr1 in sleep regulation. These mice exhibited clear evidence of sleep and circadian ...

HD is an autosomal dominant genetic disorder affecting five to ten in 100,000 people and caused by a mutation of the huntingtin (HTT) gene, which results in extended CAG trinucleotide repeats.

Melissa Beiner, M.D., SCA Clinical Development Lead at Biohaven, commented, Our NDA filing is the culmination of over 8 years of clinical research a ...